Physician profile
Jeffrey Tomaszewski
NPI 1710166244
$3,066.31
in general payments reported to CMS, 2019-2025
21 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $88.48 · 2021: $69.43 · 2022: $163 · 2023: $381 · 2024: $619 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,021.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,286.15 | 2019-2025 | Lithovue, Ams 700, Rezum Generator |
| Calyxo, INC. | $263.31 | 2024-2025 | Cvac Aspiration System |
| Intuitive Surgical, INC. | $248.65 | 2019-2025 | Da Vinci Surgical System |
| Dentsply Ih Ab | $226.01 | 2023-2025 | Lofric, Lofric, Navina Rectal Catheter Set Regular |
| Neotract INC. | $194.77 | 2019 | |
| Davol INC. | $145.45 | 2023 | Arista Ah Flexitip |
| Coloplast Corp | $143.89 | 2025 | |
| Medtronic USA, INC. | $110.11 | 2019 | |
| Cook Medical LLC | $88.48 | 2020 | |
| Ferring Pharmaceuticals INC. | $68.37 | 2024 | Adstiladrin |
| Urogen Pharma, INC. | $66.75 | 2023-2025 | Jelmyto |
| Teleflex LLC | $51.11 | 2024-2025 | Barrigel |
| Medtronic, INC. | $40.00 | 2025 | Interstim |
| Civco Medical Instruments | $26.71 | 2024 | |
| Convatec INC. | $25.67 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $18.54 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.30 | 2019 | |
| Janssen Biotech, INC. | $15.51 | 2024 | Erleada |
| Astellas Pharma US INC | $15.22 | 2024 | Xtandi |
| Myriad Genetic Laboratories, INC. | $14.31 | 2023 | Prolaris |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Tomaszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.